Dermavant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Dermavant Sciences's estimated annual revenue is currently $81.4M per year.
- Dermavant Sciences received $100.0M in venture funding in August 2018.
- Dermavant Sciences's estimated revenue per employee is $217,000
Employee Data
- Dermavant Sciences has 375 Employees.
- Dermavant Sciences grew their employee count by 40% last year.
Dermavant Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 20% | N/A | N/A |
#3 | $1.7M | 11 | -45% | N/A | N/A |
#4 | $5.3M | 34 | 0% | N/A | N/A |
#5 | $4M | 26 | -7% | N/A | N/A |
#6 | $2.5M | 16 | 129% | N/A | N/A |
#7 | $1.4M | 9 | -25% | N/A | N/A |
#8 | $2.2M | 29 | 21% | $58.2M | N/A |
#9 | $177M | 1142 | -6% | N/A | N/A |
#10 | $0.9M | 6 | 200% | N/A | N/A |
What Is Dermavant Sciences?
A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.
keywords:N/A
N/A
Total Funding
375
Number of Employees
$81.4M
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Dermavant Sciences News
This year's SOCS Scientific Symposium was co-chaired by Andrew Alexis, MD, ... Beiersdorf, Dermavant Sciences, Ortho Dermatologics, P & G,...
Dermavant Sciences presented new data from the Phase III PSOARING 3 long-term extension study of tapinarof cream for plaque psoriasis in...
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and...
Dermavant Sciences, a Long Beach CA, Durham, NC, and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding. In details, the company has entered into: a $160m revenue interest purchase and sale agreement for its investigational ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 11, 2021-- Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data fr ...
Other Companies in Phoenix
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $99.5M | 379 | 2% | N/A |
#2 | $127.9M | 379 | -3% | N/A |
#3 | $128.9M | 382 | 4% | N/A |
#4 | $105.1M | 382 | 22% | N/A |
#5 | $21180M | 386 | 0% | N/A |
Dermavant Sciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-08-29 | $100.0M | Undisclosed | NovaQuest Capital Management | Article |